Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

WVE

Phase 1

WVE-006

Alpha-1 Antitrypsin Deficiency

2025

RestorAATion-1/-2 trials. 4/30/24- CTA approval for RestorAATion-2. 8/8/24 Dosing initiated in RestorAATion-2. 10/16/17- Achieved proof-of-mechanism. 3/4/25- Second single dose cohort initiated. Multi-dosing data in 2025.

Data readout

SNTI

Phase 1

SENTI-202

Hematologic Malignancies [Acute Myeloid Leukemia]

2025

5/13/24- First patient dosed. 8/5/24- Execution of CIRM grant. 12/2/24- Reported initial clinical data. Dose escalation continuing with additional response & durability data in 2025.

Data readout

RNAC

Phase 2

Descartes-08

Systemic lupus erythematosus (SLE)

H2 2025

7/2/24- First patient dosed. 3/13/25- Data readout in H2 2025.

Data readout

PASG

Phase 1/2

PBFT02 (AAV1)

Frontotemporal dementia w/ granulin (FTD-GRN) or FTD-C9orf72

H2 2025

upliFT-D trial. 10/24/24- Interim data at ESGCT '24. 3/4/25- Dose 1 and dose 2 data in H2 2025. Seek regulatory feedback in H1 2026. Initiate dosing of FTD-C9orf72 participants in H1 2025.

Data Readout

BCYC

Phase 1/2

BT5528 (EphA2)

Solid Tumors

2025

12/14/23- Ongoing DE portion trial in mUC and ovarian cancer. Results expected in 2025.

Data readout

ARVN

Phase 3

Vepdegestrant (Mono)

Second-line-plus ER+/HER2- metastatic breast cancer (mBC)

2025

VERITAC-2 trial. 12/06/23- Host conference call to discuss SABCS presentation. 1/10/25- Topline data in Q1 2025. 3/11/25- Met primary endpoint. OS data to be reported later in the year.

Additional data readout

KZIA

Phase 2

Paxalisib (GDC-0084)

Primary CNS Lymphoma

2025

11/2/23- Reported preliminary data. 11/7/24- Initial data in 2025.

Data readout

VALN

Phase 2

VLA15

Lyme Disease

YE 2025

VALOR study. Collab w/ Pfizer. 9/7/23- Ph2 booster results. 12/4/23- Completed recruitment. 5/7/24- Topline data by YE 2025. BLA & MAA to EMA in 2026. 7/17/24- Completed primary vaccination series (3 doses). 9/3/24 Positive data from VLA15-221 Ph2 study second booster vaccination.

Data readout

RNA

Phase 1/2

Delpacibart zotadirsen (del-zota) (AOC 1044)

DMD (Duchenne muscular dystrophy), DMD44

Q4 2025

EXPLORE44 trial. 8/9/24- Reported Ph1/2 data (5mg/kg cohort). 1/13/25- OLE data in Q4 2025. 3/17/25- Reported Ph1/2 topline data and presented at 2025 MDA. BLA submission by YE 2025. Present functional data in Q4 2025.

Data readout

BBIO

Phase 3

Encaleret

ADH1 (Autosomal Dominant Hypocalcemia Type 1)

2025

CALIBRATE trial. 12/22/22- Initiated a Ph 3 pivotal study. Full enrollment in 2024 & topline data in 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20